Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics.

ABSTRACT: Despite the lack of placebo-controlled trials, glucocorticoids are considered the mainstay of initial treatment for idiopathic inflammatory myopathy (IIMs) and myositis-associated ILD (MA-ILD). Glucocorticoid-sparing agents are often given concomitantly with other immunosuppressive agents, particularly in patients with moderate or severe disease. As treatment of refractory cases of idiopathic inflammatory myopathies has been challenging, there is growing interest in evaluating newer therapies including biologics that target various pathways involved in the pathogenesis of IIMs. In a large clinical trial of rituximab in adult and juvenile myositis, the primary outcome was not met, but the definition of improvement was met by most of this refractory group of myositis patients. Rituximab use

SUBMITTER: Moghadam-Kia S 

PROVIDER: S-EPMC4945479 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature